Valeritas Holdings Inc (NASDAQ:VLRX) shares were up 7.1% during trading on Tuesday . The stock traded as high as $2.08 and last traded at $1.56. Approximately 17,963 shares traded hands during mid-day trading, a decline of 95% from the average daily volume of 373,290 shares. The stock had previously closed at $1.68.
Several research analysts have recently commented on VLRX shares. ValuEngine raised Valeritas from a “hold” rating to a “buy” rating in a report on Saturday, June 2nd. Cowen downgraded Valeritas from an “outperform” rating to a “market perform” rating in a report on Wednesday, March 28th.
The firm has a market capitalization of $31.80 million, a P/E ratio of -0.18 and a beta of 4.32. The company has a debt-to-equity ratio of -2.57, a current ratio of 2.56 and a quick ratio of 1.80.
Valeritas (NASDAQ:VLRX) last announced its earnings results on Wednesday, May 9th. The company reported ($1.72) EPS for the quarter, topping the consensus estimate of ($2.13) by $0.41. Valeritas had a negative return on equity of 1,768.69% and a negative net margin of 225.97%. The business had revenue of $6.08 million for the quarter, compared to the consensus estimate of $6.00 million. equities research analysts anticipate that Valeritas Holdings Inc will post -6.67 EPS for the current year.
In related news, insider John Edward Timberlake acquired 22,500 shares of the company’s stock in a transaction that occurred on Wednesday, April 25th. The stock was purchased at an average price of $1.67 per share, for a total transaction of $37,575.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Joseph M. Mandato acquired 20,000 shares of the company’s stock in a transaction that occurred on Thursday, May 10th. The stock was bought at an average price of $1.63 per share, with a total value of $32,600.00. The disclosure for this purchase can be found here. Insiders purchased a total of 47,500 shares of company stock valued at $78,275 in the last 90 days. 1.20% of the stock is currently owned by corporate insiders.
Valeritas Holdings, Inc, a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States and China. It offers V-Go, a wearable insulin delivery device for basal-bolus therapy. The company also develops h-Patch, a controlled delivery technology platform; Mini-Ject technology for needle-free injection systems; and Micro-Trans technology for microneedle design, fabrication, and drug delivery.
Receive News & Ratings for Valeritas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas and related companies with MarketBeat.com's FREE daily email newsletter.